VivaLNK has secured FDA clearance for its Continuous ECG platform comprising of reusable wearable ECG sensors and associated software development kit (SDK).

The reusable patch and SDK gives solution providers direct control over data.

The company claims it is the world’s first FDA-cleared wearable ECG sensor platform.

The platform allows application developers to combine with VivaLNK medical wearable sensors, forwarding data instantly to the application.

Additionally, the company’s sensors do not gather personal information.

Caretaker Medical president and CEO Jeff Pompeo said: “Caretaker is pleased to select VivaLNK as the FDA 510k cleared ECG sensor provider for our continuous wireless vital signs platform and thrilled to have a best-in-class form factor that is incredibly comfortable for the patient, easy to integrate into our system, reliable for our healthcare provider customers and allows direct control of the data flow into our secure CaretakerCloud remote patient monitoring portal.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The SDK in the platform also helps developers to combine with the FDA-cleared and CE-marked VivaLNK temperature sensor, allowing numerous vitals to be remotely observed from a single platform.

AMPS president and chief scientist Fabio Badilini said: “VivaLNK’s Continuous ECG Platform has been seamlessly integrated with the AMPS Continuous ECG Recording Suite (CER-S) allowing for the direct analysis of the recorded data, and can, therefore, be immediately adopted by the pharmaceutical industry in the context of clinical trials.”

VivaLNK offers healthcare solutions for wellness, telemedicine and medical treatment.

The company’s portfolio comprises wearable medical grade devices and data analytics applications to examine patient health.

Last August, researchers at Emory University had used VivaLNK’s ambulatory ECG patch to study autonomic function in patients undergoing coronary angiography.